Three Month Safety and Efficacy Study of TRAVATAN® Versus Travoprost Ophthalmic Solution, 0.004%

NCT01452009 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Management Decision

Conditions

Open Angle Glaucoma
Ocular Hypertension

Interventions

DRUG: Travoprost Ophthalmic Solution, 0.004% (New Formulation)
DRUG: TRAVATAN®

Sponsor

Alcon Research